Acute Myeloid Leukemia

Acute Myeloid Leukemia

Development of Multidrug Resistance in Acute Myeloid Leukemia Is Associated with Alterations of the LPHN1/GAL-9/TIM-3 Signaling Pathway

Here, study investigators prove that latrophilin-1 expression also occurs in the myeloid blasts of patients newly diagnosed with myelodysplastic syndrome when ABCB1 is overexpressed.

Long Non-Coding RNA LINC00152 Regulates Self-Renewal of Leukemia Stem Cells and Induces Chemo-Resistance in Acute Myeloid Leukemia

Herein, the lncRNA, LINC00152, is identified to be highly expressed in CD34+ LSCs and is found to regulate the self-renewal of LSCs derived from AML patients.

Frontiers in Oncology
The Correlation of Next-Generation Sequencing-Based Genotypic Profiles With Clinicopathologic Characteristics in NPM1-Mutated Acute Myeloid Leukemia

The purpose of this study is to analyze the association between NGS genotypic profiles and conventional clinicopathologic characteristics in patients with AML with NPM1 mutation.

BMC Cancer

Association Between Measurable Residual Disease in Patients With Intermediate-Risk AML and First Remission, Treatment, and Outcomes

This study suggests that clinical decisions based on dynamic measurable residual disease might be associated with improved therapy stratification and optimized postremission treatment for patients

JAMA Network
Phase 3 Randomized Trial of Chemotherapy With or Without Oblimersen in Older AML Patients

Oblimersen (G3139) can be safely added to conventional chemotherapy for older patients with AML.

Blood Advances
The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia

Study investigators examine the preclinical efficacy of a new strategy combining ABT-199 with HHT, a selective inhibitor of MCL-1 may be a promising approach for AML treatment...

Frontiers in Oncology
Long Non-Coding RNA LINC00152 Regulates Self-Renewal of Leukemia Stem Cells and Induces Chemo-Resistance in Acute Myeloid Leukemia

In this study, the lncRNA, LINC00152, is identified to be highly expressed in CD34+ LSCs and is found to regulate the self-renewal of LSCs derived from AML patients.

Frontiers in Oncology
Effect of Myeloid Progenitor Cell Product on the Risk of Infection During Induction Chemotherapy for AML

Desai et al find the addition of the myeloid progenitor cell product romyelocel-L to G-CSF reduces the incidence of infection and antimicrobial use vs G-CSF alone during induction CT in AML.

The ASCO Post
DNA-PK Inhibitor Peposertib Enhances p53-Dependent Cytotoxicity of DNA Double-Strand Break Inducing Therapy in Acute Leukemia

Study investigators examine the therapeutic potential of M3814 in combination with DSB-inducing agents in leukemia cells and a patient-derived tumor. 

Scientific Reports
Skin Biopsies in Acute Myeloid Leukemia Patients Undergoing Intensive CT are Safe and Effect Patient Management

The aim of this study was to evaluate the diagnostic yield and safety of skin biopsies obtained from adult patients with AML during hospitalization for intensive chemotherapy.

Scientific Reports
Anti-Tumor Effects of BDH1 in Acute Myeloid Leukemia

In order to find out its role in AML pathogenesis, investigators first analyze the expression levels of 10 key genes involved in ketone metabolism in AML blasts and CD34+ HSCs from healthy donors. 

Frontiers in Oncology
Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia

This study shows that ADM expression in AML associates with a stem cell phenotype, inflammatory signatures and genes related to immunosuppression, all factors that contribute to therapy resistance.

Frontiers in Oncology
Chromosomal Instability in Acute Myeloid Leukemia

This review focuses on CIN studies in AML, their prognostic results, as well as the use of CIN as a therapeutic target in AML.

Prognostic Prediction of Cytogenetically Normal Acute Myeloid Leukemia Based on a Gene Expression Model

The prognosis of cytogenetically normal AML, which is the largest AML subset, can be hard to define.

Frontiers in Oncology
Effect of DNMT3A Variant Allele Frequency and Double Mutation on Clinicopathologic Features of Patients With de novo AML

The clinicopathologic features of DNMT3A-mutated de novo AML, and the significance of variant type, variant allele frequency, and multiple concomitant DNMT3A mutations, remain poorly defined.

Blood Advances
CD52 is a Novel Target for the Treatment of FLT3-ITD-Mutated Myeloid Leukemia

Internal tandem duplication of FLT3 confers poor prognosis and is found in approximately 25% of cases of acute myeloid leukemia.

Cell Death Discovery
Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation

Study investigators aim to explore the mechanism of immune escape in AML with DNMT3A mutation. 

Frontiers in Immunology
Long Non-Coding RNA LINC01018 Inhibits the Progression of Acute Myeloid Leukemia by Targeting miR-499a-5p to Regulate PDCD4

The mRNA expression of LINC01018, miR-499a-5p and PDCD4 in AML tissues and cells was detected using reverse transcription-quantitative polymerase chain reaction.

Oncology Letters
Clinical Implications of Sequential MRD Monitoring by NGS at 2 Time Points After Chemotherapy in Patients With AML

In this study, investigators aim to examine the clinical significance of NGS MRD at 2 different time points. 

Blood Advances
Scaffold-Mediated CRISPR-Cas9 Delivery System for Acute Myeloid Leukemia Therapy

Leukemia stem cells sustain the disease and contribute to relapse in AML. Therapies that ablate LSCs may increase the chance of eliminating this cancer in patients. 

Science Advances
Measurable Residual Disease Status and Outcome of Transplant in Acute Myeloid Leukemia in Second Complete Remission: A Study by the Acute Leukemia Working Party of the EBMT

Measurable residual disease prior to HCT for AML in first complete morphological remission is an independent predictor of outcome, but few studies address CR2.

Blood Cancer Journal
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?

Allogeneic stem cell transplant represents a pivotally important treatment strategy in fit adults with AML because of its augmented anti-leukemic activity consequent upon dose intensification...

Frontiers in Immunology
SETBP1 Overexpression Acts in the Place of Class-Defining Mutations to Drive FLT3-ITD–Mutant AML

SETBP1 overexpression activates a HOXA signature and collaborates with FLT3-ITD to drive AML in the absence of class-defining mutations.

Blood Advances
The Mutual Regulatory Loop Between TPTEP1 and miR-1303 in Leukemogenesis of Acute Myeloid Leukemia

Gene expression is evaluated by quantitative real-time polymerase chain reaction or western blot. Functional assays are also performed to assess the cellular processes in AML cells.

Cancer Cell International
Leukemia Stemness and Co-Occurring Mutations Drive Resistance to IDH Inhibitors in Acute Myeloid Leukemia

Allosteric inhibitors of mutant IDH1 or IDH2 induce terminal differentiation of the mutant leukemic blasts and provide durable clinical responses in approximately 40% of AML patients with...

Nature Communications
Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia

Study investigators describe the different epigenetic, transcriptional, and metabolic states of therapy sensitive and resistant AML cell populations and LSCs, how these cell states are influenced..

Frontiers in Oncology
Mesothelin is a Novel Cell Surface Disease Marker and Potential Therapeutic Target in Acute Myeloid Leukemia

This analysis identifies a large cohort of AML-restricted genes with high expression in AML, but low to no expression in normal hematopoiesis.

Blood Advances
Allogeneic Hematopoietic Cell Transplantation With Cord Blood Versus Mismatched Unrelated Donor With Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia

Study investigators compare the allo-HCT outcomes of CBT versus single-allele-mismatched MMUD allo-HCT with post-transplant cyclophosphamide in acute myeloid leukemia.

Journal of Hematology & Oncology
MicroRNA-363-3p Promote the Development of Acute Myeloid Leukemia With RUNX1 Mutation by Targeting SPRYD4 and FNDC3B

This study aims to identify the key genes and microRNAs based on acute myeloid leukemia with RUNX1 mutation. 

A Clinical Transcriptome Approach to Patient Stratification and Therapy Selection in Acute Myeloid Leukemia

Study investigators develop and validate a clinical transcriptome-based assay for stratification of acute myeloid leukemia.

Nature Communications
Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia

This study addresses NK cell maturation in bone marrow under three conditions: a normal developmental environment, during pre-leukemic state, and during leukemic transformation.

Frontiers in Immunology
High HSPA8 Expression Predicts Adverse Outcomes of Acute Myeloid Leukemia

In this study, public datasets available from the TCGA and GEO are mined to discover the association between the expression of HSPA8 and clinical phenotypes of CN-AML.

BMC Cancer
Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

The increasingly important role of allo-SCT in the management of AML has been underpinned by two important advances.

Frontiers in Oncology

source list reference